RxDoctor Payments Data

David Ringold, MD

Nephrology · Dubuque, IANPI 1912967118

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 24.7% of the total. 2025 is the largest year on record at $218, more than ten times the $11 reported in 2020.

$469in general payments, 2019–2025

Across 24 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$116
  • Otsuka America Pharmaceutical, Inc.$106
  • Boehringer Ingelheim$78
  • Baxter Healthcare$65
  • Novartis$57
  • Calliditas Therapeutics US Inc.$23
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$46799%
  • Education$21%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$469 in reported general payments places this provider in the 60th percentile of 73 nephrology providers in Iowa.

See all nephrology providers in Iowa

Medicare billing

Part B allowed, 2024
$407,468
Medicare patients
506
Services billed
47,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin251$256,579
FarxigaDapagliflozin Propanediol311$228,296
EliquisApixaban39$30,249
Sevelamer Carbonate106$26,796
ClinolipidFat Emulsion/Olive/Soy/Phospho51$12,143
DapagliflozinDapagliflozin Propanediol21$10,225
ProsolParenteral Amino Acid 20% No.155$8,761
Cinacalcet Hcl63$8,188
Irbesartan458$8,153
Labetalol Hcl201$7,151
Nifedipine ErNifedipine228$7,121
Potassium Chloride265$6,356
LokelmaSodium Zirconium Cyclosilicate14$5,935
Furosemide647$3,906
Midodrine Hcl30$2,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$78$256,579251 claims
AstraZenecaFarxiga, Lokelma$116$234,231325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 73 nephrology providers in Iowa.

Other nephrology in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →